Rh-Endostatin (EndostarÂ®) Continuous Intravenous Infusion
Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous intravenous infusion by using venous pump can improve the compliance.
Lung Cancer
DRUG: Endostar|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Pemetrexed
ORR, objective response rate based on Recist 1.1 edition, 8 weeks
PFS, progress free survival, 8 weeks
Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous intravenous infusion by using venous pump can improve the compliance.